France: Sanofi completes acquisition of Translate Bio

Paul Hudson, CEO Sanofi

Biopharmaceutical company, Sanofi, has completed the acquisition of Translate Bio, an mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction. The acquisition, announced in August, is planned to accelerate Sanofi’s efforts in developing vaccines and therapies using mRNA technology. Translate Bio has an early-stage pipeline in cystic fibrosis and other rare…

You must be a HMI Subscriber to view this content.

Subscribe Now »